Lucentis

1
A nine letter word for hope
2
American Foundation for the Blind Headlines
3
MacuScopeTM

• Accurately measures a patients Macular
  Protective Pigment Density (MPPD)
• Low MPPD is a major risk factor for Macular
  Degeneration and is modifiable
• Pigment deficiency can NOW be identified and
  monitored decades before clinical signs and/or
  symptoms appear

4
The Science
5
The FactsOverwhelming body of evidence that

• Yellow MPP blocks high energy blue light
• has strong antioxidative properties
• resides anterior to the RPE layer and
  photoreceptors

6
Concentration of Macular Pigments

• Consists solely of 3 carotenoids
• Lutein (L), Meso-zeaxanthin (MZ) Zeaxanthin (Z)
• MZ is the dominant carotenoid at the fovea and is
  the most potent antioxidant in the macula

7
Link to AMD

• AMD Patients have low MPPD - a major risk factor
• Reasons for low MPPD include
• Genetics
• Smoking
• Dietary insufficiency
• Obesity
• Inability to absorb
• Lack of ability to convert L to MZ

8
Age and Macular Pigment
Published in Exp Eye Res. December 2006
9
Cigarette Smoking and Macular Pigment
Published in Exp Eye Res. December 2006
10
Family History of AMD and Macular Pigment
Published in Exp Eye Res. December 2006
11
Nutraceutical Supplementation

• Repigmentation of the macula reduces the risk of
  developing AMD
• Objective prevent future permanent and
  cumulative damage
• Appropriate nutraceutical supplementation can
  rebuild Macular Pigment
• a formulary containing all 3 carotenoids as found
  in LMZ3 10mg Lutein 10 mg Meso-zeaxanthin 2
  mg Zeaxanthin
• Measurable repigmentation can occur in as little
  as 6 months and usually plateaus in 2 years

12
AREDS Report 22

• Archives of Ophthalmology, Sept. 07
• Evaluated dietary intake of carotenoids, vitamins
  A, C and E and their relationship to the
  progression of AMD
• Conclusion Only dietary intake of carotenoids
  correlated with a decreased rate of progression
  for any of the four stages of AMD

13
Leading Expert

• John Nolan BSc, PhD
• Fulbright Scholar _at_ University of Georgia
• Deputy Director Post Doctoral Research Fellow,
  Waterford Institute of Technology
• PhD thesis "Determinants of Macular Pigment in
  Healthy Subjects" was the largest cross-sectional
  study of its type in the world
• Significant findings from his thesis
• Healthy middle-aged offspring of patients with
  age-related macular degeneration (AMD) have a
  significant lack of macular pigment
• This finding suggests that the observed lack of
  pigment may predispose the sons and daughters of
  AMD sufferers to this disease
• Appropriate dietary modification may delay, or
  even prevent the onset of disease

             
14
Leading Expert

• Richard A. Bone PhD, Professor, Dept. of Physics,
  Florida International University
• Research Interests Experimental Biophysics -
  Physics of the eye and visual system MP and its
  possible relationship with AMD non-invasive
  measurement of the MP Cumulative light
  distribution on the human retina.
• Recent Publications
• Bone, Landrum, Guerra, and Ruiz. (2003) Lutein
  and zeaxanthin dietary supplements raise macular
  pigment J. Nutr. 133, 992-998.
• Krinsky, Landrum, Bone. (2003) Biologic
  mechanisms of the protective role of lutein
  Annu. Rev. Nutr. 23, 171-201.
• Bone, Landrum (2004) Heterochromatic flicker
  photometery. Arch. Biochem. Biophys. 430,
  137-142.
• Bone, Landrum, Gibert. (2004) Macular pigment and
  the edge hypothesis of flicker photometry. Vision
  Res. 44, 3045-3051.
• Rosenthal, Kim, de Monastario, Thompson, Bone et
  al (2006) Dose-ranging study of luteinInvest.
  Ophthalmol. Vis. Sci. 47, 5227-5233.
• Bone, Landrum, Cao, Howard, Alvarez-Calderon.
  (2006) Macular pigment responseNutr. Metab.
  412.
• Bone, Brener, Gibert (2007) Macular pigment,
  photopigments, and melaninVision Res. 47,
  3259-3268.Bone and Draper (2007) Optical
  anisotropy of the human corneaApplied Optics 46,
  8351-8357.

15
Testimonials on Technology

• Its a great tool for identifying patients at
  risk for AMD.  There is great relief on their
  faces when they get the results and find out they
  are not at risk.  The thing patients fear most
  is going blind.   For those who are at risk,
  theyre thrilled that there is something that can
  be done about it through supplementation and
  re-testing six months later. 
• We are seen as the technological leader in the
  community because no one else has this.  Were
  getting patients from across the state wanting to
  take the test.                                
                                                 
                                                 
                                                    
        
•  Elaine Happ OD, Monticello, MN

16
Testimonials on Technology

• The MacuScope uses technology that needs to be
  available in every practice. It allows doctors to
  provide preventative eye care which may be vital
  to keeping quality vision for our patients. Our
  MacuScope raises the standard of care we provide
  and has been a welcome addition to our practice.
• Wes Kemp, O.D., Bolivar, MO

17
Testimonials on Technology

• Trying to prevent blindness is a big part of
  what we do. You feel good about being an O.D.
  when a patient returns for their six month
  re-check, their macular protective pigment has
  increased, and you get a great big thank you!
  Its wonderful to give patients hope
• Harriet Pelton, O.D., Bloomfield Twp, MI

18

• Help your patients
• at risk for AMD
• The MacuScopeTM
• Helping to Preserve the Worlds Vision

Amsler Grid with Advanced AMD